PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
Authors:
- Mark NovasMNMark Novas
- Christoph TerborgCTChristoph Terborg
- 9 April 2015
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 372 (15) , 1476-1478
Abstract
We report the case of a 54-year-old woman with multiple sclerosis who was treated with delayed-release dimethyl fumarate (DMF; Tecfidera, Biogen Idec) and who died on October 13, 2014, from complications related to aspiration pneumonia and progressive multifocal leukoencephalopathy (PML) with severe, prolonged lymphocytopenia.Keywords
This publication has 2 references indexed in Scilit:
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple SclerosisNew England Journal of Medicine, 2012
- Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapiesArthritis & Rheumatism, 2012